Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement
Annovis Bio’s lead compound, buntanetap, shows significant enhanced cognitive benefits when combined with GLP-1 agonist dulaglutide in a mouse model Buntanetap targets neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases GLP-1 agonists, typically used for diabetes, weight loss, and heart conditions, have shown potential in addressing neuroinflammation and neurodegeneration The combination treatment results were compelling: While buntanetap alone restored cognitive function to 100% and dulaglutide alone…